Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00260793
Status:
UNKNOWN
Last Update Posted:
2006-02-03
First Post:
2005-12-01
Brief Title:
Open Label High Dose Ropinirole Requip Study for Patients With Parkinsons Disease
Sponsor:
Agarwal Pinky MD
Organization:
Colorado Neurology
Study Overview
Official Title:
Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinsons Disease
Status:
UNKNOWN
Status Verified Date:
2005-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to see if subjects with Parkinsons disease who are experiencing motor fluctuations on and off states and dyskinesias involuntary excessive movements would benefit from a higher dose of Requip as compared to the maximum FDA approved dose of dopamine agonist drugs including Requip Mirapex and Permax Requip as used in this study is investigational which means it has not been approved by the US Food and Drug Administration FDA at this dose level
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None